Cell cycle arrest by oxaliplatin on cancer cells

Fundamental and Clinical Pharmacology

Volumn 21, Issue 2, 2007, Pages 165-172

  William Faltaos, Sara ^a   Rouillard, Dany ^b   Lechat, Philippe ^a   Bastian, Gérard ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT CURIE   (France)

Author keywords

Cell cycle; Cytotoxicity; Oxaliplatin

Indexed keywords

OXALIPLATIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL STRAIN A 549; CELL STRAIN HT29; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BROMODEOXYURIDINE; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; INFUSIONS, INTRAVENOUS; ORGANOPLATINUM COMPOUNDS; PROPIDIUM;

EID: 33947635511     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00462.x     Document Type: Article

References (25)

1. Misset J.L., Bleiberg H., Sutherland W., Bekradda M., Cvitkovic E. Oxaliplatin clinical activity: a review. Crit. Rev. Oncol. Hematol. (2000) 35 75-93.
2. Culy C.R., Clemett D., Wiseman L.R. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs (2000) 60 895-924.
3. Rixe O., Ortuzar W., Alvarez M. et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol. (1996) 52 1855-1865.
4. Pendyala L., Creaven P.J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. (1993) 53 5970-5976.
5. Holmes J., Stanko J., Varchenko M. et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol. Sci. (1998) 46 342-351.
6. Raymond E., Lawrence R., Izbicka E., Faivre S., Von Hoff D.D. Activity of oxaliplatin against human tumor colony-forming units. Clin. Cancer Res. (1998) 4 1021-1029.
7. Dabholkar M., Reed E. Cisplatin. Cancer. Chemother. Biol. Response Modif. (1996) 16 88-110.
8. Parker R.J., Eastman A., Bostick-Bruton F., Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. (1991) 87 772-777.
9. Ciccarelli R.B., Solomon M.J., Varshavsky A., Lippard S.J. In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein crosslinking, and inhibition of replication. Biochemistry (1985) 24 7533-7540.
10. Sorenson C.M., Barry M.A., Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J. Natl Cancer. Inst. (1990) 82 749-755.
11. Nichols C.R., Williams S.D., Loehrer P.J. et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J. Clin. Oncol. (1991) 9 1163-1172.
12. Fujikane T., Shimizu T., Tsuji T., Ishida S., Ohsaki Y., Onodera S. Flow cytometric analysis of the kinetic effects of cisplatin on lung cancer cells. Cytometry (1989) 10 788-795.
13. William-Faltaos S., Rouillard D., Lechat P., Bastian G. Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines. Anticancer Res. (2006) 26 2093-2099.
14. Maindrault-Goebel F., de Gramont A., Louvet C. et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur. J. Cancer (2001) 37 1000-1005.
15. Levi F., Misset J.L., Brienza S. et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer (1992) 69 893-900.
16. Mishima M., Samimi G., Kondo A., Lin X., Howell S.B. The cellular pharmacology of oxaliplatin resistance. Eur. J. Cancer (2002) 38 1405-1412.
17. Arnould S., Guichard S., Hennebelle I., Cassar G., Bugat R., Canal P. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line. Biochem. Pharmacol. (2002) 64 1215-1226.
18. Reardon J.T., Vaisman A., Chaney S.G., Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bisaceto-ammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. (1999) 59 3968-3971.
19. Arnould S., Hennebelle I., Canal P., Bugat R., Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur. J. Cancer (2003) 39 112-119.
20. Smits V.A., Medema R.H. Checking out the G(2)/M transition. Biochim. Biophys. Acta (2001) 1519 1-12.
21. Zeghari-Squalli N., Raymond E., Cvitkovic E., Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin. Cancer Res (1999) 5 1189-1196.
22. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer (2003) 3 155-168.
23. Vaisman A., Masutani C., Hanaoka F., Chaney S.G. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. Biochemistry (2000) 39 4575-4580.
24. Carrato A., Gallego J., Diaz-Rubio E. Oxaliplatin: results in colorectal carcinoma. Crit. Rev. Oncol. Hematol. (2002) 44 29-44.
25. Gil-Delgado M.B.G., William-Faltaos S, Paule B et al. Final results of pharmacokinetic study of oxaliplatin and capecitabine combination for advanced colorectal cancer. Proceedings ASCO N° 143.00 ed, 2005.